Biogen (BIIB) volatility elevated on report of Sanofi-Aventis buyout
Tweet Send to a Friend
Biogen (Nasdaq: BIIB) is recently up $2.18 to $48.90. Sanofi-Aventis (NYSE: SNY) could target Allergan ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
